Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 4/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681967 | 1.00 | TUBB1 (0.61) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL10176577 | 1.00 | TUBB1 (0.61) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL13681966 | 1.00 | TUBB1 (0.61) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL27400494 | 0.94 | TUBB1 (0.52) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL88616 | 0.87 | TUBB1 (0.47) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL13681965 | 0.87 | TUBB1 (0.47) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL57429 | 0.87 | TUBB1 (0.47) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL15434941 | 0.87 | TUBB1 (0.47) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL57950 | 0.87 | TUBB1 (0.47) | TUBB1CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL17733995 | 0.87 | TUBB1 (0.47) | TUBB1CYP3A4CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885CYP3A4 249/4885CYP2D6 279/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | TUBB1 1668/4885CYP3A4 194/4885CYP2D6 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.